



Revista de la Sociedad Española de Nefrología

journal homepage: [www.revistanefrologia.com](http://www.revistanefrologia.com)

## Original article

# Q1 KFRE as a criterion for referral to advanced chronic kidney disease Q2 consultations

## Q3 *El KFRE como criterio de remisión a las consultas de enfermedad renal crónica avanzada*

Q4 Eduardo Gallego-Valcarce \*, Angela Rey-Cárdenas, Eva López-Melero,  
Ana María Tato-Ribera, Deborah Roldan, Sofia López San Román, Ángel Méndez Abreu, Clara  
Cases-Corona, Enrique Gruss

Q5 Servicio de Nefrología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain

## ARTICLE INFO

## Keywords:

Chronic kidney disease  
End state kidney disease  
Kidney failure risk equation  
KFRE  
Prognostic model

## ABSTRACT

**Background and objective:** The KDIGO guidelines recommend as a criterion for referral to ACKD consultations a risk > 10% of requiring renal replacement therapy before 2 years. This risk should be assessed with externally validated prediction models. The prediction models (KFRE) and the Grams model meet these requirements.

In an ACKD unit with a remission criterion of eGFR < 30 mL/min, we proposed a retrospective cohort study to evaluate whether the application of a KFRE > 10% as a remission criterion allows differentiation of patients according to their clinical and analytical characteristics and their evolution.

**Materials and methods:** We studied 573 patients followed in the ACKD clinic for at least 4 years. In the first consultation we classified them into two groups according to their 2-year KFRE: < or ≥10%. We compared their clinical and analytical characteristics and whether the prognoses made by Grams' model at baseline matched the observed evolution. Both groups were analyzed according to two age ranges: older and younger than 75 years.

**Results:** Patients with KFRE ≥ 10% (53.4%), with respect to those with KFRE < 10%, were significantly younger and their annual eGFR loss was greater. They had different evolution: at 2 years, 38.9% vs 3% ( $p < 0.05$ ) started RRT and 45.8% vs 79.8% ( $p < 0.05$ ) remained in the clinic; at 4 years, 60.7% vs 15.6% ( $p < 0.05$ ) started RRT and 16.7% vs 52.3% ( $p < 0.05$ ) remained in the clinic.

In the group with KFRE < 10% those ≥75 years vs <75 years initiated RRT and died previously in a significantly different proportion at 2 years: 1.2 vs 6.1 % and 23.7 vs 6.1 % respectively ( $P < 0.05$ ).

In the group with KFRE ≥ 10% those ≥75 years and those <75 years initiated RRT and previously died in a significantly different proportion at 2 years: 25.9 vs 46.4 % and 32.1 vs 5.7 % respectively ( $P < 0.05$ ).

Prediction models predicted all these differences quite accurately.

**Conclusions:** A KFRE ≥ 10% at 2 years would be an appropriate criterion for referral to ACKD consultations, since it would select a group of patients who are really going to require RRT in the medium term, regardless of their age, and would avoid the referral of patients at low risk of requiring RRT, mainly elderly patients.

## RESUMEN

**Antecedentes y objetivo:** Las guías KDIGO recomiendan como criterio de remisión a las consultas de ERCA un riesgo > 10% de precisar tratamiento renal sustitutivo antes de 2 años. Este riesgo se debe evaluar con modelos de predicción validados externamente. Los modelos de predicción (KFRE) y el de Grams cumplen estos requisitos.

En una unidad de ERCA con un criterio de remisión de FGe < 30 ml/min, planteamos un estudio de cohortes retrospectivo para evaluar si la aplicación de un KFRE > 10% como criterio de remisión permite diferenciar a los pacientes según sus características clínicas y analíticas y su evolución.

## Palabras clave:

Enfermedad renal crónica  
Ecuación de riesgo de insuficiencia renal  
KFRE  
Modelos de predicción

\* Corresponding author.

E-mail address: [egallegov@telefonica.net](mailto:egallegov@telefonica.net) (E. Gallego-Valcarce).

<https://doi.org/10.1016/j.nefro.2026.501412>

Received 27 April 2025; Accepted 10 September 2025

Available online xxx

2013-2514/© 2025 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Pacientes y métodos:** Estudiamos 573 pacientes seguidos en la consulta de ERCA al menos durante 4 años. En la primera consulta los clasificamos en dos grupos según su KFRE a dos años:  $< 10\%$  o  $\geq 10\%$ . Comparamos sus características clínicas y analíticas y si los pronósticos efectuados por el modelo de Grams al inicio se ajustan a la evolución observada. Ambos grupos se han analizado según dos rangos de edad: mayores y menores de 75 años.

**Resultados:** Los pacientes con KFRE  $\geq 10\%$  (53,4%), con respecto los que tenían KFRE  $< 10\%$ , eran significativamente más jóvenes y su pérdida anual de FGe fue mayor. Tuvieron diferente evolución: a los 2 años iniciaron TRS el 38,9% vs 3% ( $p < 0,05$ ) y permanecieron en la consulta el 45,8% vs el 79,8% ( $p < 0,05$ ), a los 4 años iniciaron TRS el 60,7% vs 15,6% ( $p < 0,05$ ), permanecieron en la consulta el 16,7% vs 52,3% ( $p < 0,05$ ).

En el grupo con KFRE  $< 10\%$  los  $\geq 75$  años frente a los  $< 75$  años iniciaron TRS y fallecieron previamente en una proporción significativamente diferente a los 2 años: 1,2 vs 6,1 % y 23,7 vs 6,1 % respectivamente ( $P < 0,05$ ).

En el grupo con KFRE  $\geq 10\%$  los  $\geq 75$  años y los  $< 75$  años iniciaron TRS y fallecieron previamente en una proporción significativamente diferente a los 2 años: 25,9 vs 46,4 % y 32,1 vs 5,7 % respectivamente ( $P < 0,05$ ).

Los modelos de predicción pronosticaron todas estas diferencias con bastante exactitud.

**Conclusiones:** Un KFRE  $\geq 10\%$  a dos años sería un adecuado criterio de remisión a las consultas de ERCA, ya que seleccionaría un grupo de pacientes que realmente van a precisar TRS a medio plazo, independientemente de su edad y evitaría la remisión de enfermos con escaso riesgo de precisar TRS, fundamentalmente pacientes de edad avanzada.

## Introduction

The 2012 *Kidney Disease: Improving Global Outcomes* (KDIGO) guidelines on the evaluation and management of chronic kidney disease (CKD) recommend classifying CKD into different grades according to the estimated glomerular filtration rate (eGFR) and the microalbuminuria/creatinine ratio in the urine.<sup>1</sup> This classification allows for the assignment of a relative risk of developing different complications regarding the specific degree of CKD. However, although we are aware of the relative risk of initiating renal replacement therapy (RRT) for a specific stage of CKD, the absolute risk of initiating RRT for each patient included in that specific stage of CKD varies in a wide range.

For this reason, the new edition of the 2024 KDIGO guidelines emphasizes the need to individualize the management of patients not only by their stage of CKD but also by determining their absolute risk of requiring RRT.<sup>2</sup> In patients with stage G3–G5 CKD, RRT has been recommended, with a grade of recommendation of 1A, such that the absolute risk of requiring RRT is estimated through equations that have been externally validated.

The kidney failure risk equation (KFRE)<sup>3</sup> is the most widely used model for predicting the need for RRT because of its high accuracy and extensive validation in different populations.<sup>4–6</sup>

The use of the KFRE as a valid tool to predict the need to initiate RRT has allowed for the KDIGO guidelines to recommend a risk of initiating RRT within 2 years above 10% as a criterion for referral for multidisciplinary advanced chronic kidney disease (ACKD) clinic consultations.<sup>2</sup> Thus, an ideal group of patients would be selected who would obtain the maximum benefit from these highly specialized consultations, and this method would avoid the referral of patients with a low risk of progression who would not benefit from their early inclusion in ACKD consultations.

The KFRE has also been validated in different age groups,<sup>7</sup> although in elderly patients with high mortality, the need to initiate RRT may be overestimated.<sup>8</sup>

In ACKD consultations, elderly patients are becoming increasingly prevalent, and their management constitutes a major challenge owing to the fact that as age increases, the risk of death exceeds that of requiring RRT even in very advanced stages of CKD.<sup>9</sup> It has been reported that over the age of 75 years, the majority of patients with stage IV CKD exhibit a higher risk of death than that of initiating RRT.<sup>10,11</sup>

The Grams prediction model<sup>12</sup> is also a validated model that, in addition to predicting entry into RRT, provides an estimate of the risk of mortality that can be useful in guiding management in populations with high mortality, such as patients with CKD G4+, as well as patients demonstrating advanced age and a high degree of comorbidities.<sup>6,13,14</sup>

The objective of this study was to evaluate the consequences of using a 10% risk threshold of requiring RRT within 2 years as a criterion for receiving a ACKD clinic referral, as estimated by using the KFRE. For this purpose, the evolution of patients with a KFRE value higher and lower than 10% was compared after considering their age groups. Similarly, whether the prognostic predictions of the Grams model were fulfilled in each of these groups was analyzed.

## Population and methods

### Population

A retrospective cohort study was conducted in adult patients (older than 18 years) who were referred to the ACKD clinic of the Alcorcón Foundation University Hospital between January 1, 2013, and December 31, 2020. The follow-up of the patients lasted until December 31, 2024, thus guaranteeing a minimum follow-up time of 4 years.


### Inclusion criteria

All incident patients who participated in an ACKD consultation during the indicated time period, who were older than 18 years, and who presented an eGFR  $< 30$  mL/min were included.

### Exclusion criteria

The following patients were excluded from the study:

- 1 Patients referred after an episode of acute renal failure who recovered renal function and achieved an eGFR  $> 30$  mL/min.
- 2 Transplant patients with renal dysfunction who were referred for initiating RRT.
- 3 Patients who initiated RRT on the same day as their first ACKD consultation.
- 4 Patients who were lost to follow-up after the first consultation.
- 5 Patients without sufficient analytical data to perform prognostic calculations on their evolution.



**Figure 1.** Population flow diagram.

ACKD: advanced chronic kidney disease; ARF: acute renal failure; RRT: renal replacement therapy.

A total of 622 patients met the inclusion criteria; of these patients, 49 were excluded because they met any of the abovementioned criteria. Therefore, the final study population consisted of 573 patients. The population flow diagram is presented in Fig. 1.

### Study design

This was a retrospective cohort study in which data different clinical, analytical and evolutionary variables that were collected in the ACKD clinic were analyzed and recorded in a database in each visit.

### Collection of clinical data and follow-up

In the first consultation, the affiliation data and clinical characteristics of the patients, including age, sex, etiology of CKD, history of cardiovascular pathology (such as stroke, ischemic heart disease, heart failure and peripheral vascular disease), diabetes mellitus, history of smoking and other comorbidities necessary for the calculation of the Charlson comorbidity index, were recorded. Similarly, data involving blood pressure, body mass index (BMI) and basic analytical parameters were obtained, and patients were classified according to the CKD stage.

The frequency of consultations was mainly adjusted according to the clinical evolution of the patient, as well as changes in symptoms and eGFR values, at the discretion of the attending physician. In patients with CKD stage G4A1, a minimum of three visits per year was ensured according to the recommendations of the KDIGO guidelines.<sup>1</sup>

In the follow-up consultations, the analytical results, blood pressure data, BMI and relevant clinical events were systematically collected. The serial measurements of the eGFR values at each visit allowed for the calculation of the rate of progression of renal deterioration in each patient via simple linear regression using the least squares method.

### Evolutionary events

The following clinical outcomes were considered in the evolution of patients treated in the ACKD clinic:

- Renal failure, which was defined as the start of RRT (either through

hemodialysis, peritoneal dialysis or the performance of a preventive kidney transplant).

- Death (whether it occurred before or after the initiation of RRT).
- Continuation in the ACKD clinic (without requiring RRT or having died before starting RRT).

These evolutionary events were recorded at 2, 4 and 5 years from the date of admission to the ACKD clinic, with the aim of evaluating the different predictive models of evolution.

### Predictive models of evolution

In the first consultation, two prognostic prediction models were applied to estimate the clinical evolution of the patients: the KFRE model with 4 variables (calibrated for the non-North American population), which was applied at 2 and 5 years; and the Grams model, which was applied at 2 and 4 years.

The KFRE model estimates the probability of requiring RRT within 2 or 5 years in patients with an eGFR < 60 mL/min. The adjusted version for non-North American populations was used, which was developed by the Tangri group<sup>3</sup>; moreover, it utilizes four variables, including age (in years), sex, eGFR (calculated via the CKD-EPI formula, in mL/min) and the albumin/creatinine ratio in the urine (mg/g).

The Grams model is applied to patients with an eGFR < 30 mL/min and offers a more detailed prediction by estimating the probabilities of initiating RRT; dying before initiating RRT; remaining with CKD without initiating RRT or dying; or dying after the initiation of RRT. The forecast is calculated for time periods of 2 and 4 years. The variables included in the model were age, sex, race, eGFR, systolic blood pressure, history of cardiovascular disease, diabetes mellitus status, the urinary albumin/creatinine ratio and history of smoking. The individual probabilities were calculated by using the multinomial formulas provided by the Grams group.<sup>12</sup>

Based on the KFRE result at 2 years, incident patients were classified into two groups according to their risk of needing RRT: low risk (KFRE < 10%) and high risk (KFRE ≥ 10%).

Subsequently, their clinical and analytical characteristics, initial prognosis and observed evolution were compared, with the aim of assessing whether this risk threshold is adequate as a criterion for referral for an ACKD consultation. In addition, both groups were

subdivided according to age (<75 years and ≥75 years) to analyze whether age affects the evolution or accuracy of the predictive model.

Ethical approval

The study was performed in accordance with the ethical principles established in the Declaration of Helsinki and was approved by the Clinical Research Ethics Committee of the Alcorcón Foundation University Hospital (Alcorcón, Madrid, Spain) with reference number 22/157. Given the retrospective nature of the study and the high proportion of patients who were no longer receiving follow-ups (either due to death or having initiated RRT [dialysis or transplantation] in other centers), the ethics committee waived the need to obtain informed consent.

Statistical analysis

Continuous variables are expressed as the means ± standard deviations when they are normally distributed or as the medians and interquartile ranges when they are nonnormally distributed. The categorical variables are presented as absolute frequencies and percentages. The normality of the continuous variables was verified by using the Kolmogorov-Smirnov test. For the comparison of means, the Student's *t*-test was used in the case of a normal distribution, and the Mann-Whitney test was used when the distribution was not normal. Categorical variables were compared by using the chi-square test. A *p* value < 0.05 was considered to indicate statistical significance.

To evaluate the performance of the predictive models, a discrimination analysis of both the KFRE model (at 2 and 5 years) and the Grams model (at 2 and 4 years) was performed after considering the initiation of RRT, continuation in the ACKD clinic without RRT or death and death before the initiation of RRT as events. The discriminative capacity of each model was evaluated by using the area under the receiver operating characteristic (ROC) curve (AUC or *C* statistic), along with its corresponding 95% confidence interval (CI). Acceptable discrimination was considered if the AUC value was ≥0.70, and it was considered to be excellent if it was ≥0.80. The calibration of the models (specifically, the degree of agreement between the predicted probabilities and the observed events) was analyzed by using the Hosmer-Lemeshow test.<sup>15</sup>

Statistical analysis was performed by using IBM SPSS Statistics for Windows, version 22.0 (IBM Corp., Armonk, NY, USA).

To estimate the annual loss of renal function, the slope of the linear regression of the eGFR as a function of follow-up time at the ACKD consultation was calculated. This slope represents the estimated annual change in the eGFR, which was obtained by using a least squares linear regression model including all of the eGFR determinations performed during outpatient follow-up, following the recommendations of various authors.<sup>16-18</sup>

Determinations made during hospital admission were excluded from the analysis. Similarly, seven patients with <four valid determinations of eGFR were not included in the analysis. In total, 566 regression slopes were analyzed, with an average number of determinations per patient of 12.64 ± 6.45. Among these patients, 502 (88.7%) exhibited a negative slope, thereby indicating loss of renal function during the follow-up period.

Results

Evaluation of the performance of the predictive models

Table 1 shows the discrimination of the two predictive models by calculating the area under the ROC curve with a confidence interval of 95%. The prediction capability of the onset of RRT within 2 years of

**Table 1**  
Discrimination of KFRE with 4 variables at 2 and 5 years and the Grams model results at 2 and 4 years.

	AUC (95% CI)
RRT at 2 years	0.872 (0.838–0.905)
RRT at 5 years	0.810 (0.773–0.848)
GRAMS Model	
RRT at 2 years	0.877 (0.845–0.909)
RRT at 4 years	0.839 (0.807–0.872)
Death before RRT at 2 years	0.746 (0.694–0.797)
Death before RRT at 4 years	0.755 (0.712–0.797)
Death before or after RRT at 2 years	0.725 (0.673–0.777)
Death before or after RRT at 4 years	0.738 (0.696–0.781)
Continuation in the ACKD clinic at 2 years	0.758 (0.716–0.799)
Continuation in the ACKD clinic at 4 years	0.748 (0.709–0.788)

RRT: renal replacement therapy; ACKD: advanced chronic kidney disease.

the two models demonstrated an excellent discrimination, with an AUC value of 0.87 being observed; moreover, discrimination at 4 and 5 years decreased, although it remained >0.8. In the prediction of death before initiating RRT and continuation in the ACKD clinic performed by the Grams model, an acceptable AUC value was maintained at approximately 0.75. These values are similar to those reported in the literature.<sup>8,13,14</sup>

Comparison between patients with low and high risks of initiating RRT within 2 years

Upon arrival at the ACKD consultation, 267 patients (46.6%) demonstrated a KFRE < 10% and were classified as patients with a low risk of initiating RRT; the remaining 306 patients (53.4%) demonstrated a KFRE ≥ 10% and were classified as patients at a high risk of initiating RRT. Compared with high-risk patients, low-risk patients were significantly older, had a higher Charlson Index, smoked less, exhibited less hypertension, and demonstrated higher eGFR values, whereas their proteinuria and annual decrease in eGFR values were significantly lower (Table 2).

The observed progression at 2, 4 and 5 years was significantly different between patients who were at low risk and those who were at high risk (Table 3); specifically, at 2 years, 3% vs. 38.9% had initiated RRT (*p* < 0.05), whereas at 4 years, 52.3% vs. 16.7% had initiated RRT (*p* < 0.05), and 32.1% vs. 22.6% had died before initiating RRT (*p* < 0.05).

These different evolutions were fairly accurately predicted by the prediction models (Table 3). The evolution of low-risk patients observed at 2 and 4 years is shown in Fig. 2, along with the prediction made by the Grams model upon initial ACKD clinic consultation for the same time periods. The model demonstrated a good predictive capability for the initiation of RRT, continuation of treatment at the ACKD clinic or death before initiating RRT. The main discrepancy was observed in the initiation of RRT at 4 years, which is possibly attributable to the inclusion of patients with autosomal dominant polycystic kidney disease (ADPKD) in the low-risk group. These patients (when presenting with nonproteinuric nephropathy) were classified as low risk by the model, although in clinical practice, they require RRT at a high percentage. If we excluded these patients, the rate of initiation of RRT at 4 years would be 11.3% observed vs. 9.6% predicted.

When the risk of initiating RSRD was observed to be high, the agreement between the prediction and the observed evolution was not as precise (Fig. 3). The percentage of patients initiating RRT was much greater than that predicted by the Grams model and increased over the years. At 2 years, the prediction of initiating RRS was 25.2%; however, 38.9% initiated RRT. At 4 years, the difference increased at 39.2% predicted vs. 60.7% observed. The observed mortality was always lower than predicted.



**Table 2**  
Comparison of the clinical and analytical characteristics at the beginning of follow-up in the ACKD consultation of patients with a risk of initiating RRT within 2 years (estimated via the KFRE with 4 variables) < 10% vs. those with a risk equal to or greater than 10%.

Risk of SDB at 2 years	< 10%	≥ 10%	p
n/%	267/46.6%	306/53.4%	
Age, years	76.1 (10.5)	68.8 (13.7)	0.00
< 75 years, %	36.7	63.4	0.00
Sex, men, %	60.1	70.8	0.010
Diabetes, %	54.7	59.5	0.247
Smoker, %	11.6	20.3	0.005
ECV, %	56.6	49.0	0.072
Charlson Index	8 (6–10)	7 (5–9)	0.000
SBP, mmHg	139.4 (20.5)	148.9 (23.7)	0.000
DBP, mmHg	71.9 (11.7)	77.2 (12.9)	0.000
IMC, kg/m <sup>2</sup>	28.7 (25.8–32.3)	28.5 (25–32.3)	0.258
eGFR, mL/min	23.8 (20.2–23.8)	18.0 (14.6–21.7)	0.000
Mau/cro ratio, mg/g	48.6 (10.9–153.7)	999.2 (428–1949)	0.000
A3%	15.4	82.4	0.000
G5%	3.0	28.4	0.000
Annual eGF decrease, mL/min/year	–3.1 (3.1)	–5.9 (5.3)	0.000
Albumin, g/dL	4.2 (4–4.2)	4.1 (3.8–4.3)	0.000
Hemoglobin, g/dL	12.1 (11.1–13.1)	11.6 (10.7–12.7)	0.000
PTH, pg/mL	93.9 (55.1–133.5)	123.8 (76.3–211.3)	0.000
LDL Cholesterol, mg/dL	73 (59–92)	73 (58–94)	0.789

A3: patients with a microalbuminuria/creatinine ratio in the urine (mau/cro) > 300 mg/g; CVD: cardiovascular disease; G5: patients with an eGFR by CKD-EPI < 15 mL/min; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; eGFR: estimated glomerular filtration rate; PTH: parathyroid hormone. The data are shown as the means (standard deviations), medians (interquartile ranges) or numbers and percentages. The annual decrease in the eGFR is expressed as the mean decrease in the eGFR in patients who exhibited decreases in the eGFR during follow-up (in the low-risk group, 81.2% demonstrated decreases in the eGFR during follow-up; in the high-risk group, 95% demonstrated decreases).

**Table 3**  
Comparison of the prognosis at the beginning of follow-up in the ACKD clinic of patients with a risk of initiating RRT within 2 years of < 10% compared to those who had a risk equal to or greater than 10%. We also compared the evolution observed at 2, 4 and 5 years in patients in both groups.


Risk of SDB at 2 years	< 10%	≥ 10%	p
<b>Calculated prognosis</b>			
<i>By KFRE</i>			
At two years	3.7 (1.7–6.3)	21.5 (15.1–35.6)	0.000
Five years	13.7 (6.4–22.3)	60.7 (47–81.9)	0.000
<i>By Grams at two years</i>			
RRT	4.9 (2.4–7.3)	21.7 (16.1–32.7)	0.000
Death before RRT	16.3 (9.8–22.2)	17.8 (8.3–29.3)	0.152
Continuation in the ACKD clinic	79.3 (71.5–84.9)	55.4 (44.3–66.8)	0.000
Death before or after RRT	17.3 (10.7–23.6)	22.5 (12.7–36.1)	0.000
<i>By Grams at four years</i>			
SRRD	9.8 (4.9–14.3)	36.0 (26.4–50.3)	0.000
Death before RRT	30.8 (20.2–41.7)	29.8 (12.6–45.6)	0.238
Continuation in the ACKD clinic	59.5 (46.9–70.9)	28.1 (18.7–41.5)	0.000
Death before or after RRT	33.7 (21.9–46.0)	44.7 (27.9–62.9)	0.000
<b>Observed evolution</b>			
<i>At two years</i>			
RRT	3.0	38.9	0.000
Death before RRT	17.2	15.4	0.545
Continuation in the ACKD clinic	79.8	45.8	0.000
Death before or after RRRT	17.6	19.3	0.606
<i>At four years</i>			
SRRD	15.6	60.7	0.000
Death before RRT	32.1	22.6	0.012
Continuation in the ACKD clinic	52.3	16.7	0.000
Death before or after RRT	34	35.5	0.698
<i>At five years</i>			
SRR <sup>a</sup>	21.2	65.5	0.000

RRT: renal replacement therapy; ACKD: advanced chronic kidney disease. The prognostic estimates are presented as medians (interquartile ranges), and the observed evolutions are presented as percentages.  
<sup>a</sup> Patients did not reached 5 years of follow-up were excluded (those with visits in the ACKD clinic in 2020). Therefore, the calculation was performed in 498 patients (231 with risk < 10 and 267 with risk ≥ 10).

Comparison of patients with KFRE < 10% according to age group (< 75 years vs. ≥ 75 years)

Among patients with a low risk of initiating RRT, those patients ≥ 75 years demonstrated more cardiovascular comorbidities and a higher Charlson comorbidity index, along with smoking at a lower

frequency; moreover, their analytical characteristics were similar to those of patients < 75 years, with a similar rate of decrease in the eGF being observed, in addition to being referred to the ACKD clinic with lower eGF values (Table 4). With respect to evolution (Table 5), the mortality before the need for RRT was observed to be high (23.7% at 2 years), with a minimal need to initiate RRT (1.2% at 2 years), whereas patients < 75 years exhibited a significantly different



**Figure 2.** Observed evolution and initial prognosis according to the Grams model at 2 years (A) and at 4 years (B) in patients with a risk <10% of initiating RRT. The calculated prognosis (a quantitative variable) is expressed as the mean, and its standard deviation is presented. The observed evolution (qualitative variable) represents the percentage of patients in each category. The Hosmer-Lemeshow test was used to compare the goodness of fit between the calculated prognosis and observed evolution (a p value closer to 1 indicates a better fit; if  $p < 0.05$ , the fit is not significant). A) RRT:  $p = 0.523$ ; death before RRT:  $p = 0.933$ ; continuation in the ACKD clinic:  $p = 0.189$ . B) RRT:  $p = 0.516$ ; death before RRT:  $p = 0.392$ ; continuation in the ACKD clinic:  $p = 0.023$ . RRT: renal replacement therapy; ACKD: advanced chronic kidney disease.

**Table 4**

Comparison of the clinical and analytical characteristics at the beginning of follow-up in the ACKD clinic of patients with a risk of initiating RRT within 2 years of less than or greater than 10% (calculated via the KFRE with 4 variables), according to the specific age group: younger or older than 75 years.

Risk of SDB at 2 years	< 10%	<i>p</i>	≥ 10%	<i>p</i>
Age groups	< 75 years		< 75 years	
<i>n</i> /%	98/36.7		194/64.4	
Age, years	65.1 (8.3)	0.000	61.2 (11.2)	0.000
Sex, men, %	60.2	0.905	74.5	0.093
Smoker, %	17.3	0.026	25.8	0.002
Diabetes, %	52.0	0.509	57.2	0.289
ECV, %	43.9	0.001	44.8	0.055
Charlson Index	6 (4–8)	0.000	6 (4–8)	0.000
SBP, mmHg	136.6 (19)	0.084	146.8 (24.8)	0.035
DBP, mmHg	75.5 (12)	0.000	79.3 (12.9)	0.000
IMC, kg/m <sup>2</sup>	28.9 (25.8–33.1)	0.358	28.8 (25.1–32.5)	0.839
eGFR, mL/min	24.5 (20.6–75)	0.040	18.9 (14.9–23.0)	0.000
Mau/cro ratio, mg/g	49.9 (15.1–140.9)	0.771	111.2 (44.0–1.951)	0.263
A3%	15.3	0.986	84	0.314
G5%	0	0.029	24.7	0.060
Annual eGF decrease, mL/min/year	–3.5 (3.3)	0.253	–6.1 (5.4)	0.431
Albumin, g/dL	4.3 (4.1–4.4)	0.003	4.1 (3.8–4.3)	0.491
Hemoglobin, g/dL	12.2 (11.4–13.2)	0.181	11.7 (10.7–12.7)	0.457
PTH, pg/mL	91 (59–132)	0.876	125.5 (70.7–229.2)	0.453
LDL Cholesterol, mg/dL	75.5 (60.5–91.5)	0.581	72.0 (57.5–94.5)	0.637

The data are shown as the means (standard deviations), medians (interquartile ranges), or numbers and percentages.


A3: patients with a microalbuminuria/creatinine ratio in the urine (mau/cro) > 300 mg/g; CVD: cardiovascular disease; G5: patients with an eGFR by CKD-EPI < 15 mL/min; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; eGFR: estimated glomerular filtration rate; PTH: parathyroid hormone.

mortality and requirement for SRRD (with a mortality rate before RRT within 2 years of 6.1% and an RRT of 6.1%). This evolution was quite accurately predicted via the prediction models (Table 5).

When comparing the evolution observed at 2 and 4 years with that predicted by the Grams model in the same time periods, in the two age groups (Table 5 and Appendix A; Figs. 1 and 2 of the Supplement), we observed that in both cases, the prediction and evolution were very similar, although in individuals < 75 years, the initiation of RRT was observed to be greater than estimated, especially in the long term (29.5% vs. 13.7% at 4 years, which was likely conditioned by the inclusion of patients with ADPKD, due to the fact that if we excluded these patients, the differences were reduced at 19.2% vs. 13.04%).

*Comparison of patients with KFRE ≥ 10% according to age group (< 75 years vs. ≥ 75 years)*

Among patients with a KFRE ≥ 10% who were aged ≥ 75 years, those patients aged < 75 years demonstrated significantly greater



**Figure 3.** Observed evolution and initial prognosis according to the Grams model at 2 years (A) and at 4 years (B) in patients with a risk ≥10% of initiating RRT. The calculated prognosis (a quantitative variable) is expressed as the mean, and its standard deviation is presented. The observed evolution (qualitative variable) represents the percentage of patients in each category. The Hosmer-Lemeshow test was used to compare the goodness of fit between the calculated prognosis and observed evolution (a p value closer to 1 indicates a better fit; if  $p < 0.05$ , the fit is not significant). A) RRT:  $p = 0.813$ ; death before RRT:  $p = 0.620$ ; continuation in the ACKD clinic:  $p = 0.207$ . B) RRT:  $p = 0.703$ ; death before RRT:  $p = 0.556$ ; V:  $p = 0.047$ . RRT: renal replacement therapy; ACKD: advanced chronic kidney disease.

RRT: renal replacement therapy; ACKD: advanced chronic kidney disease.

hypertension, a higher Charlson comorbidity index, and a lower frequency of smoking; moreover, their analytical characteristics were similar, with a similar rate of deterioration of the eGFR being observed, although they were able to achieve an ACKD with a lower eGFR (Table 4).

In terms of evolution, both groups initiated RRT in very high percentages at both 2 and 4 years, although patients < 75 years accounted for a significantly greater proportion (46.4% vs. 25.9% at 2 years and 71.6% vs. 41.4% at 4 years, respectively;  $p < 0.05$ ) (Table 5). Patients aged ≥ 75 years demonstrated significantly greater mortality prior to the initiation of RRS than those < 75 years (32.1% vs. 5.7% at 2 years and 45% vs. 9.8% at 4 years;  $p < 0.05$ ). The persistence in AKD consultations at 4 years was only 18.6% for patients < 75 years and 13.5% for those ≥ 75 years ( $p = 0.26$ ). The prediction models detected the same differences in terms of mortality and initiation of SRRD between the two groups.

The evolution observed at 2 and 4 years and that predicted by the Grams model in the same time periods in the two age groups are

**Table 5**  
Comparison of the prognosis of patients younger or older than 75 years at the start of follow-up in the ACKD clinic, according to the risk group involving the initiation of RRT within 2 years (as estimated via the KFRE with 4 variables). Additional comparison of the evolution observed at 2, 4 and 5 years in the patients in the respective groups.

Risk of RRT at 2 years		10%		p	p ≥ 10%		p
Age groups		< 75 years	≥ 75 years		< 75 years	≥ 75 years	
<b>Calculated prognosis</b>							
<i>Por KFRE</i>							
At two years		4.4 (2.5–6.8)	3.3 (1.4–5.8)	0.011	24.3 (15.3–38.5)	18.9 (14.7–26.8)	0.001
Ar five years		16.2 (9.4–23.9)	12.3 (5.4–20.8)	0.010	65.9 (47.5–84.8)	55.6 (46–70.1)	0.010
<i>Per Grams at two years</i>							
SRRD		6.8 (4.3–9.1)	3.6 (1.8–6.5)	0.000	24.6 (17.6–36.1)	18.4 (13.4–24.5)	0.000
Death before RRT		9.1 (6.4–12.7)	20.1 (16.1–26.3)	0.000	10.7 (5.3–17.1)	32.0 (28–39.6)	0.000
Continuation in the ACKD clinic		84.1 (80.2–88.0)	75.3 (67.7–81.4)	0.000	63.1 (50.4–71.5)	47.0 (38–54.5)	0.000
Death before or after RRT		9.9 (7.0–14.0)	21.4 (16.8–28.0)	0.000	15.1 (8.5–21.8)	39.9 (32.5–46.9)	0.000
<i>Per Grams at four years</i>							
RRT		13.7 (9–18.2)	6.9 (3.7–11.8)	0.000	42.6 (32.4–57.7)	28.0 (20.1–35.1)	0.000
Death before RRT		18.1 (11.9–24.7)	37.1 (30.2–48.1)	0.000	17.8 (8.2–28.8)	49.5 (41–59.4)	0.000
Continuation in the ACKD clinic		68.4 (59.7–76.0)	53.8 (41.5–65.0)	0.000	36.3 (23.9–47.5)	20.3 (14.3–26.8)	0.000
Death before or after RRT		20.6 (14.8–30.5)	41.3 (32.5–52.9)	0.000	32.3 (19.6–44.2)	66.3(59.1–73.6)	0.000
<b>Observed evolution</b>							
<i>At two years</i>							
RRT		6.1	1.2	0.023	46.4	25.9	0.000
Death before RRT		6.1	23.7	0.000	5.7	32.1	0.000
Permanence in ACKD		87.8	75.1	0.013	47.9	42	0.312
Death before or after RRRT		7.1	23.7	0.001	8.8	37.5	0.000
<i>At four years</i>							
SRRD		29.5	7.8	0.000	71.6	41.4	0.000
Death before RRT		13.7	42.5	0.000	9.8	45	0.000
Permanence in ACKD		56.8	49.7	0.266	18.6	13.5	0.256
Death before or after RRRT		16.8	43.7	0.000	21.8	59.5	0.000
<i>At five years</i>							
RRT <sup>a</sup>		36.5	12.3	0.000	78.4	42.7	0.000

RRT: renal replacement therapy; ACKD: advanced chronic kidney disease.  
The prognostic estimates are presented as medians (interquartile ranges), and the observed evolutions are presented as percentages.  
<sup>a</sup> Patients who did reached 5 years of follow-up were excluded(those with visits in the ACKD clinic in 2020). Therefore, the calculation was performed in 498 patients (231 with risk < 10 and 267 with risk ≥ 10).

described in Table 5 and shown in Appendix A (Figs. 3 and 4 of the Supplement). We observed that in those patients older than 75 years, the observed evolution was quite similar to the predicted evolution, although patients initiated RRR at a higher percentage than what was predicted, especially at 4 years (41.4% vs. 28%). However, in high-risk patients <75 years, the prediction model was not very accurate with respect to predicting observed evolution, due to the fact that in both time periods, the differences were considered to be important in the three possible evolutions (initiation of RRT, exit from the study before initiating RRT and continuation in the ACKD clinic), with the beginning of RRS representing the greatest difference (71.6% at 4 years vs. 42.6% predicted).

Discussion

In this study, we described how an estimated risk of requiring RRT within 2 years of 10% (which was calculated by using the KFRE model in patients with CKD disease stages of G4 or higher) serves as an adequate threshold for referral to ACKD consultations. Patients with a risk lower than 10% do not benefit from this referral, due to the fact that they demonstrate a very low probability of requiring RRT and conversely demonstrate a high risk of mortality, especially elderly patients (as predicted by the Grams model). In contrast, patients with a risk equal to or greater than 10% truly benefit from referral to ACKD consultations (regardless of their age) due to their high probability of initiating RRT in the short or medium term.  
CKD is associated with a significant increase in the risks of cardiovascular events, mortality and progression to terminal renal failure requiring RRT.<sup>19</sup> The rate of progression and incidence of these events increase as renal function deteriorates, although there is considerable interindividual variability.<sup>20</sup> Therefore, the accurate identification of patients with an increased risk of progression is

essential to properly plan their follow-up and prepare the initiation of RRT (involving dialysis or transplantation). In this context, the use of predictive models in high-risk patients (such as those with CKD stages of G4 or higher) has attracted special interest.<sup>21</sup>  
Among the multiple available models, the KFRE and the Grams models are the most commonly used because of their ease of calculation, good prognostic accuracy and wide validation in different populations.<sup>4,22</sup> The KFRE can exclusively predict the probability of the initiation of RRT in patients with an eGFR < 60 mL/min but does not consider death as a competing event, which can lead to an overestimation of the risk of RRT in populations with high mortality.<sup>23</sup> Conversely, the Grams model is specifically designed for patients with CKD G4+, in consideration of the initiation of RRT and death as competing events; thus, it provides a more complete prognosis regarding mortality, the initiation of RRT and continuation in the ACKD clinic.  
Both models have been simultaneously evaluated in patients with CKD G4+<sup>8,14</sup>; specifically, the Grams model has been investigated in elderly patients with CKD G4+<sup>13</sup> and the KFRE has been evaluated as a function of age in this population.<sup>5,7</sup> With respect to stage G5 CKD in the elderly population, both models have been simultaneously compared.<sup>24,25</sup> Unlike these studies, our research encompasses a broader population (including patients with CKD G4A1 to G5A3, thereby generating two groups that are comparable in terms of clinical and evolution characteristics; moreover, these patients were classified according to a risk of RRT within 2 years of greater or less than 10%, which is threshold that is suggested by the KDIGO guidelines.<sup>2</sup> In addition, we stratified both groups by age (<75 and ≥75 years), with this analysis not previously being performed with both models together.  
Due to this design, we confirmed that a risk threshold of 10% within 2 years is adequate for referral for an ACKD consultation. The inclusion of patients with KFRE < 10% results in referring a

considerable number of individuals with a very low probability of requiring RRT in the short or medium term. These patients, who demonstrated eGFR values  $< 30$  mL/min but also demonstrated low proteinuria levels and an annual loss of moderate renal function, remained in the ACKD clinic for a long duration. Among these patients, elderly patients with more comorbidities represented the predominant group, with significant mortality prior to the initiation of RRT being observed. In this group, the prediction of the Grams model has demonstrated good accuracy, which aligns with previous studies reporting of adequate calibration for risks lower than 20%.<sup>8,14</sup>

Conversely, patients with a KFRE  $\geq 10\%$  demonstrated a considerable annual decrease in the eGFR, which translates to a high probability of requiring RRT in the short or medium term. In general, these patients demonstrated lower eGFR values; more proteinuria and hypertension; and a greater decrease in eGFR. Moreover, males and active smokers were the predominant groups among these patients. Within this group, elderly patients exhibited clinical and analytical characteristics that were similar to those of younger patients; additionally, they demonstrated a high rate of initiation of RRT. Therefore, age should not be an exclusive criterion for early referral to ACKD consultations, although the high comorbidity and mortality associated with this subgroup should be considered.

When the Grams model was applied to this high-risk population, several limitations were observed, as previously reported.<sup>13,14,25</sup> In our study, this model tended to underestimate the risk of initiation of RRT, especially in elderly patients with high mortality and longer-term prognoses. Similar results were obtained by Provost et al.<sup>25</sup> in elderly patients with CKD G5, who reported suboptimal calibration and discrimination. With respect to mortality, the calibration in our cohort was somewhat better than that described in the literature,<sup>13,14,24</sup> although similar to other studies, we observed that predicted mortality was overestimated compared with observed mortality.

Our study demonstrates important strengths, such as a homogeneous follow-up performed by a small group of nephrologists throughout the study period, with minimal patient loss being reported. The simultaneous application of both models allows for a comprehensive risk assessment and the revalidation of these models in a broader Spanish population than the population that we previously examined in 2023.<sup>6</sup> However, this study has several limitations. For example, it is a unicentric and retrospective study; moreover, the subdivision by age and risk generates subgroups with reduced sizes, which limits the statistical power. In addition, the high-risk group (KFRE  $\geq 10\%$ ) included patients with wide ranges of risk, which may explain the discrepancies between the observed and calculated risks. The definition of the initiation of RRT was based on the original criteria of the models, although in current clinical practice, the indication for conservative treatment in elderly individuals is becoming increasingly common. Finally, patients did not receive current treatments such as SGLT2-i, GLP1-a or Nimra at significantly high rates; thus, the generalization of these findings to populations receiving these therapies should be performed with caution.

## Conclusions

In our population, the adoption of a KFRE  $\geq 10\%$  within 2 years as a criterion for referral to ACKD consultations is appropriate.

Referrals of patients with a KFRE  $< 10\%$  results in including a large number of patients who will not require RRT in the short and medium term. In this group, the Grams model provides accurate prognoses, especially in elderly individuals, with this model predicting a low probability of initiating RRT and a high probability of remaining in the ACKD clinic or dying before requiring RRT, thus indicating little benefit from referral.

In contrast, patients with a KFRE  $\geq 10\%$  demonstrate a high probability of initiating RRT in the short to medium term, although the Grams model tended to underestimate this need and overestimated mortality and continuation in the ACKD clinic. Regardless of age, these patients clearly benefit from referral to ACKD clinics because of their high risk of requiring RRT.

## CRedit authorship contribution statement

EGV designed the study. EGV, ARC, and SLSR collected the data. EGV performed the analysis. EGV, ARC, ELM, AMTR, DR, AMA, CCC, and EG analyzed and interpreted the data. EGV wrote the article and has final responsibility for its content. All of the authors contributed to the review and final approval of the manuscript.

## Financing

This research has not received specific support from public sector agencies, the commercial sector or nonprofit entities.

## Ethical considerations

The present study was approved by the CEIm of the Hospital Universitario Fundación Alcorcón (N. 22/157) and was performed in accordance with the Declaration of Helsinki, the *International Council for Harmonization guidelines for Good Clinical Practice* and Spanish laws.

## Declaration of competing interest

The authors declare that they have no conflicts of interest.

## Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.nefro.2026.501412>.

## References

1. KDIGO\_2012\_CKD\_GL.pdf [Accessed 29 March 2025]. Available from: [https://kdigo.org/wp-content/uploads/2017/02/KDIGO\\_2012\\_CKD\\_GL.pdf](https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf).
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int.* 2024;105(4 Suppl):S117–314, <http://dx.doi.org/10.1016/j.kint.2023.10.018>
3. Tangri N, Grams ME, Levey AS, Coresh J, Appel LJ, Asto BC, et al. Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis. *JAMA.* 2016;315:164, <http://dx.doi.org/10.1001/jama.2015.18202>
4. Ramspek CL, de Jong Y, Dekker FW, van Diepen M. Towards the best kidney failure prediction tool: a systematic review and selection aid. *Nephrol Dial Transplant.* 2020;35:1527–38, <http://dx.doi.org/10.1093/ndt/gfz018>
5. Hallan SI, Rifkin DE, Potok OA, Katz R, Langlo KA, Bansal N, et al. Implementing the European Renal Best Practice Guidelines suggests that prediction equations work well to differentiate risk of end-stage renal disease vs. death in older patients with low estimated glomerular filtration rate. *Kidney Int.* 2019;96:728–37, <http://dx.doi.org/10.1016/j.kint.2019.04.022>
6. Gallego-Valcarce E, Shabaka A, Tato-Ribera AM, Landaluze-Triska E, León-Poo M, Roldán D, et al. External validation of the KFRE and Grams prediction models for kidney failure and death in a Spanish cohort of patients with advanced chronic kidney disease. *J Nephrol.* 2024;37:429–37, <http://dx.doi.org/10.1007/s40620-023-01819-1>
7. Hundemer GL, Tangri N, Sood MM, Clark EG, Canney M, Edwards C, et al. The effect of age on performance of the kidney failure risk equation in advanced CKD. *Kidney Int Rep.* 2021;6:2993–3001, <http://dx.doi.org/10.1016/j.ekir.2021.09.006>
8. Ramspek CL, Evans M, Wanner C, Drechsler C, Nicholas C, Chesnaye NC, et al. Kidney failure prediction models: a comprehensive external validation study in patients with advanced CKD. *JASN.* 2021;32:1174–86, <http://dx.doi.org/10.1681/ASN.2020071077>
9. Farrington K, Covic A, Aucella F, Clyne N, de Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease



- stage 3b or higher (eGFR < 45 mL/min/1.73 m<sup>2</sup>). *Nephrol Dial Transplant*. 2016;31 Suppl 2:iii1–66, <http://dx.doi.org/10.1093/ndt/gfw356>
10. O'Hare AM, Choi AI, Bertenthal D, Bacchetti P, Garg AX, Kaufman JS, et al. Age affects outcomes in chronic kidney disease. *J Am Soc Nephrol*. 2007;18:2758–65, <http://dx.doi.org/10.1681/ASN.2007040422>
  11. De Nicola L, Minutolo R, Chiodini P, Borrelli S, Zoccali C, Postorino M, et al. The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care. *Kidney Int*. 2012;82:482–8, <http://dx.doi.org/10.1038/ki.2012.174>
  12. Grams ME, Sang Y, Ballew SH, Carrero JJ, Djurdjev O, Heerspink HJL, et al. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. *Kidney Int*. 2018;93:1442–51, <http://dx.doi.org/10.1016/j.kint.2018.01.009>
  13. Ramspek CL, Boeke R, Evans M, Heimbürger O, Snead CM, Caskey FJ, et al. Predicting kidney failure, cardiovascular disease and death in advanced CKD patients. *Kidney Int Rep*. 2022;7:2230–41, <http://dx.doi.org/10.1016/j.ekir.2022.07.165>
  14. Thanabalasingam SJ, Iliescu EA, Norman PA, Day AG, Akbari A, Hundemer GL, et al. Independent external validation and comparison of death and kidney replacement therapy prediction models in advanced CKD. *Kidney Med*. 2022;4:100440, <http://dx.doi.org/10.1016/j.xkme.2022.100440>
  15. Hosmer DW Jr, Lemeshow S, Sturdivant RX. *Applied logistic regression*. Available from: 3rd edition, John Wiley & Sons, Inc.; 2013 <https://onlinelibrary.wiley.com/doi/book/10.1002/9781118548387>.
  16. Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. *JAMA*. 2014;311:2518–31, <http://dx.doi.org/10.1001/jama.2014.6634>
  17. Sumida K, Kovesdy CP. Disease trajectories before ESRD: implications for clinical management. *Semin Nephrol*. 2017;37:132–43, <http://dx.doi.org/10.1016/j.semnephrol.2016.12.003>
  18. Boucquemont J, Heinze G, Jager KJ, Oberbauer R, Leffondre K. Regression methods for investigating risk factors of chronic kidney disease outcomes: the state of the art. *BMC Nephrol*. 2014;15:45, <http://dx.doi.org/10.1186/1471-2369-15-45>
  19. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2020;395:709–33, [http://dx.doi.org/10.1016/S0140-6736\(20\)30045-3](http://dx.doi.org/10.1016/S0140-6736(20)30045-3)
  20. Hsu C-Y, Vittinghoff E, Lin F, Shlipak MG. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. *Ann Intern Med*. 2004;141:95–101, <http://dx.doi.org/10.7326/0003-4819-141-2-200407200-00007>
  21. Eckardt KU, Bansal N, Coresh J, Evans M, Grams ME, Herzog CA, et al. Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int*. 2018;93:1281–92, <http://dx.doi.org/10.1016/j.kint.2018.02.006>
  22. Lerner B, Desrochers S, Tangri N. Risk prediction models in CKD. *Semin Nephrol*. 2017;37:144–50, <http://dx.doi.org/10.1016/j.semnephrol.2016.12.004>
  23. Ramspek CL, Teece L, Snell KIE, Evans M, Riley RD, van Smeden M, et al. Lessons learnt when accounting for competing events in the external validation of time-to-event prognostic models. *Int J Epidemiol*. 2022;51:615–25, <http://dx.doi.org/10.1093/ije/dyab256>
  24. Prouvot J, Pambrun E, Antoine V, Couchoud C, Vigneau C, Roche S, et al. Low performance of prognostic tools for predicting death before dialysis in older patients with advanced CKD. *J Nephrol*. 2021;35:993–1004, <http://dx.doi.org/10.1007/s40620-021-01180-1>
  25. Prouvot J, Pambrun E, Couchoud C, Vigneau C, Roche S, Allot V, et al. Low performance of prognostic tools for predicting dialysis in elderly people with advanced CKD. *J Nephrol*. 2021;34:1201–13, <http://dx.doi.org/10.1007/s40620-020-00919-6>